文献速递炎症性肠病

系统综述与Meta分析:免疫抑制剂与生物制剂减少克罗恩病和溃疡性结肠炎住院与手术的比较疗效

Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis.
PubMed 文献 · Aliment Pharmacol Ther · 2016-11-10

该系统综述与网状Meta分析纳入1980年1月至2016年5月发表的7项随机对照试验(5项克罗恩病、2项溃疡性结肠炎),比较抗TNF生物制剂、阿扎硫嘌呤、维得利珠单抗与安慰剂对住院和手术的影响。在克罗恩病中,抗TNF生物制剂显著降低住院(OR 0.46,95%CI 0.36-0.60)和手术(OR 0.23,95%CI 0.13-0.42),阿扎硫嘌呤和维得利珠单抗无统计学显著降低;在溃疡性结肠炎中,抗TNF生物制剂显著降低住院(OR 0.48,95%CI 0.29-0.80)和手术(OR 0.67,95%CI 0.46-0.97)。

要点

  • 克罗恩病中抗TNF生物制剂显著降低住院(OR 0.46)和手术(OR 0.23),阿扎硫嘌呤与维得利珠单抗无统计学显著降低。
  • 溃疡性结肠炎中抗TNF生物制剂显著降低住院(OR 0.48)和手术(OR 0.67)。
  • 阿扎硫嘌呤在预防克罗恩病相关住院方面劣于英夫利西单抗和阿达木单抗(概率>97.5%)。

核心结论

  • 在克罗恩病和溃疡性结肠炎中,抗TNF生物制剂可降低住院 odds 约一半、手术 odds 降低33-77%。
  • 阿扎硫嘌呤和维得利珠单抗未显示类似改善,但可靠结论可能受随机对照试验数量少的限制。

研究设计与样本

  • 系统综述,检索MEDLINE/PubMed 1980年1月至2016年5月发表的随机对照试验,评估生物制剂或免疫调节剂治疗炎症性肠病的疗效。
  • 共纳入7项随机对照试验(5项克罗恩病、2项溃疡性结肠炎),比较三种生物制剂和一种免疫调节剂与安慰剂。
  • 采用随机效应贝叶斯网状Meta分析进行配对比较。

主要发现

  • 克罗恩病中,抗TNF生物制剂较安慰剂显著降低住院(OR 0.46,95%CI 0.36-0.60)和手术(OR 0.23,95%CI 0.13-0.42)。
  • 克罗恩病中,阿扎硫嘌呤或维得利珠单抗未观察到统计学显著降低。
  • 阿扎硫嘌呤在预防克罗恩病相关住院方面劣于英夫利西单抗和阿达木单抗(概率>97.5%)。
  • 溃疡性结肠炎中,抗TNF生物制剂较安慰剂显著降低住院(OR 0.48,95%CI 0.29-0.80)和手术(OR 0.67,95%CI 0.46-0.97)。
  • 活性治疗之间的配对比较无统计学显著差异。

局限性

  • 可靠结论可能受随机对照试验数量少的限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) have a progressive course leading to hospitalisation and surgery. The ability of existing therapies to alter disease course is not clearly defined. AIM: To investigate the comparative efficacy of currently available inflammatory bowel disease (IBD) therapies to reduce hospitalisation and surgery. METHODS: We conducted a systematic review in MEDLINE/PubMed for randomised controlled trials (RCT) published between January 1980 and May 2016 examining efficacy of biological or immunomodulator therapy in IBD. We performed direct comparisons of pooled proportions of hospitalisation and surgery. Pair-wise comparisons using a random-effects Bayesian network meta-analysis were performed to assess comparative efficacy of different treatments. RESULTS: We identified seven randomised controlled trials (5 CD; 2 UC) comparing three biologics and one immunomodulator with placebo. In CD, anti-TNF biologics significantly reduced hospitalisation [Odds ratio (OR) 0.46, 95% confidence interval (CI) 0.36-0.60] and surgery (OR 0.23, 95% CI 0.13-0.42) compared to placebo. No statistically significant reduction was noted with azathioprine or vedolizumab. Azathioprine was inferior to both infliximab and adalimumab in preventing CD-related hospitalisation (>97.5% probability). Anti-TNF biologics significantly reduced hospitalisation (OR 0.48, 95% CI 0.29-0.80) and surgery (OR 0.67, 95% CI 0.46-0.97) in UC. There were no statistically significant differences in the pair-wise comparisons between active treatments. CONCLUSIONS: In CD and UC, anti-TNF biologics are efficacious in reducing the odds of hospitalisation by half and surgery by 33-77%. Azathioprine and vedolizumab were not associated with a similar improvement, but robust conclusions may be limited due to paucity of RCTs.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Mao EJ, Hazlewood GS, Kaplan GG, et al. Systematic review with meta-analysis: comparative efficacy of immunosuppressants and biologics for reducing hospitalisation and surgery in Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther. 2016. PMID: 27862107. doi:10.1111/apt.13847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。